Loading clinical trials...
Loading clinical trials...
Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness
Conditions
Interventions
L-Citrulline
Placebo
Locations
1
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Start Date
October 15, 2020
Primary Completion Date
August 30, 2021
Completion Date
September 30, 2021
Last Updated
February 22, 2023
NCT06931938
NCT06007495
NCT04707729
NCT06938217
NCT05078034
NCT07452406
Lead Sponsor
Asklepion Pharmaceuticals, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions